Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198608 | 0.82 | CA2 (0.37) | CA2CA1CA9CA12CA4 | |
| SCHEMBL18503493 | 0.79 | CA1 (0.37) | CA2CA1CA9CA12CA4 | |
| SCHEMBL17198607 | 0.77 | CA1 (0.31) | CA2CA1 | |
| SCHEMBL15025272 | 0.75 | CA1 (0.34) | CA2CA1CA9 | |
| SCHEMBL15025154 | 0.75 | CA1 (0.34) | CA2CA1CA9 | |
| SCHEMBL8905408 | 0.74 | CA2 (0.40) | CA2CA1CA9CA12CA4 | |
| SCHEMBL7438361 | 0.74 | CA2 (0.40) | CA2CA1CA9CA12CA4 | |
| SCHEMBL7432541 | 0.74 | CA2 (0.40) | CA2CA1CA9CA12CA4 | |
| SCHEMBL23902747 | 0.73 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL12408763 | 0.73 | CA2 (0.39) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | CA2 3346/4885CA1 4837/4885CA9 4064/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | CA2 3435/4885CA1 4843/4885CA9 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.